To the Editor.—
The results of Townsend, Eilber, and Morton (236:2187, 1976) in the adjuvant immunotherapy of patients with soft tissue sarcomas are truly impressive, even though their clinical trial was nonrandomized.We use chemoimmunotherapy for the treatment of metastatic soft tissue sarcomas. The chemotherapy consists of vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride, and dacarbazine. When the total dose of 500 mg/sq m doxorubicin hydrochloride is reached, it is replaced by dactinomycin. Chemotherapy is given on days 1 through 5, and immunotherapy is given on days 17 and 24; courses are repeated at 28-day intervals. Immunotherapy consists of 5×108 viable units of scarified BCG (Chicago) and of intracutaneous inoculations of allogeneic cultured sarcoma cell lysates, ie, "viral oncolysates." Viral antigenic units budding through the membrane of tumor cells serve as stable helper antigens to labile tumor antigens; therefore, in cell membrane preparations or lysates of virally infected tumor cells, tumor
Sinkovics JG. Immunotherapy With Viral Oncolysates for Sarcoma. JAMA. 1977;237(9):869. doi:10.1001/jama.1977.03270360031003
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: